GLAUKOS Corp GKOS revenue by segment, product and geography
In its fiscal year ending 2025-12-31, GLAUKOS Corp reported revenue across 1 business segments; the largest, Development And Commercialization Of Ophthalmic Therapies, was $507M, 100.0% of the filed sum (+32.3% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Development And Commercialization Of Ophthalmic Therapies$507M100.0%+32.3% yoy
Members sum to the consolidated $507M for this period.
- Glaucoma$421M83.0%+38.8% yoy
- Corneal Health$86.4M17.0%+7.7% yoy
Members sum to the consolidated $507M for this period.
- United States$375M73.9%+38.9% yoy
- Outside the United States$132M26.1%+16.8% yoy
Members sum to the consolidated $507M for this period.
- Development And Commercialization Of Ophthalmic Therapies$186M100.0%+49.5% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.